LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

Lilly has also submitted marketing applications for Omvoh in Crohn's disease around the globe, including in the European Union and Japan. Additional global regulatory submissions are planned.

News provided by Eli Lilly and Company Dec 13, 2024, 8:11 AM ET The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the ...

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) By Eli Lilly and Company The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior ...

Lilly has also submitted Omvoh in the U.S. for approval to treat adults with moderately to severely active Crohn's disease, with a decision expected in the first half of 2025 INDIANAPOLIS, Dec. 13 ...

Omvoh delivered significant improvement in bowel urgency, reported by people with UC as one of the most disruptive symptoms Lilly's first approved treatment for a type of inflammatory bowel disease ...

--Eli Lilly and Company announced today that the U.S. Food and Drug Administration has approved Omvoh™ infusion/ injection, the first and only interleukin-23p19 antagonist for the treatment of ...